Evidence map›Paper›PMID 35846039›Full record

ArticleEJHaem2022

A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA.

Lale Kostakoglu, Federico Dalmasso, Paola Berchialla, Larry A Pierce, Umberto Vitolo, Maurizio Martelli, Laurie H Sehn, Marek Trněný, Tina G Nielsen, Christopher R Bolen and 6 more

Registry-linked trialAbstract read
In one paragraph

Article in EJHaem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01287741 (A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01287741 phase3terminatednot on this map

A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

TypeinterventionalSponsorHoffmann-La RocheRan2011 to 2018Enrolled1,418ConditionsDiffuse Large B-Cell LymphomaArmsRituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine
3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lale KostakogluDepartment of Radiology and Medical Imaging University of Virginia Charlottesville Virginia USA.ORCID https://orcid.org/0000-0002-2419-348X
Federico DalmassoMedical Physics Division Santa Croce e Carle Hospital Cuneo Italy.
Paola BerchiallaDepartment of Clinical and Biological Sciences University of Turin Turin Italy.
Larry A PierceDepartment of Radiology University of Washington Seattle Washington USA.
Umberto VitoloMultidisciplinary Oncology Outpatient Clinic Candiolo Cancer Institute Candiolo Italy.
Maurizio MartelliHematology Department of Translational and Precision Medicine Sapienza University Rome Italy.
Laurie H SehnBC Cancer Center for Lymphoid Cancer and the University of British Columbia Vancouver British Columbia Canada.
Marek Trněný1st Faculty of Medicine Charles University General Hospital Prague Czech Republic.
Tina G NielsenF. Hoffmann-La Roche Ltd Basel Switzerland.
Christopher R BolenGenentech, Inc. South San Francisco California USA.
Deniz SahinF. Hoffmann-La Roche Ltd Basel Switzerland.
Calvin LeeGenentech, Inc. South San Francisco California USA.
Tarec Christoffer El-GalalyF. Hoffmann-La Roche Ltd Basel Switzerland.ORCID https://orcid.org/0000-0002-4406-380X
Federico MattielloF. Hoffmann-La Roche Ltd Basel Switzerland.
Paul E KinahanDepartment of Radiology University of Washington Seattle Washington USA.
Stephane ChauvieDepartment of Clinical and Biological Sciences University of Turin Turin Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Image texture analysis (radiomics) uses radiographic images to quantify characteristics that may identify tumour heterogeneity and associated patient outcomes. Using fluoro-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT)-derived data, including quantitative metrics, image texture analysis and other clinical risk factors, we aimed to develop a prognostic model that predicts survival in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) from GOYA (NCT01287741). Image texture features and clinical risk factors were combined into a random forest model and compared with the international prognostic index (IPI) for DLBCL based on progression-free survival (PFS) and overall survival (OS) predictions. Baseline FDG-PET scans were available for 1263 patients, 832 patients of these were cell-of-origin (COO)-evaluable. Patients were stratified by IPI or radiomics features plus clinical risk factors into low-, intermediate- and high-risk groups. The random forest model with COO subgroups identified a clearer high-risk population (45% 2-year PFS [95% confidence interval (CI) 40%-52%]; 65% 2-year OS [95% CI 59%-71%]) than the IPI (58% 2-year PFS [95% CI 50%-67%]; 69% 2-year OS [95% CI 62%-77%]). This study confirms that standard clinical risk factors can be combined with PET-derived image texture features to provide an improved prognostic model predicting survival in untreated DLBCL.

Indexed as

diffuse large B‐cell lymphomaimaginglymphoid malignanciesquantitative PETradiomics

Identifiers

PMID35846039
PMCPMC9175666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.